HIV and Psoriasis

Badger, Joanna; Berger, Timothy G.; Gambla, Charles; Koo, John

doi:10.1007/978-1-4612-3966-6_5

Cited by 4 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, epidermal CD8 C T cells, like dermal T-cells, display a restricted repertoire, suggesting again that an antigen-specific immune response drives the skin expansion of the subset [16]. Likewise, the hypothesis of a contribution of CD8 C T lymphocytes to the pathogenesis of psoriasis is reinforced by findings in forms of the disease occurring in individuals infected with the human immunodeficiency virus [17]. In this model, even though the incidence and severity of HIV-related psoriasis has been lowered by the wide usage of highly active antiretroviral therapy, the parallel worsening courses of skin symptoms and of quantitative and qualitative alterations affecting CD4 C T cells, and the striking predominance of CD8 C T lymphocytes both in dermis and epidermis argue against the exclusive deleterious role of T H 1 cells [18].…”

Section: The Role Of Adaptive Immunity In Psoriasismentioning

confidence: 88%

Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity

Bachelez

2005

Journal of Autoimmunity

View full text Add to dashboard Cite

Section: The Role Of Adaptive Immunity In Psoriasismentioning

confidence: 88%

Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity

Bachelez

2005

Journal of Autoimmunity

View full text Add to dashboard Cite

“…[51][52][53] Psoriasis may present for the first time in advanced HIV infection, when CD4-cell count is less than 100 cells per µL, 54 and could even be the initial clinical manifestation of HIV infection. 53 However, psoriasis also tends to spontaneously improve during end-stage AIDS. 52,55 The relationship between HIV infection and psoriasis is complicated.…”

Section: Psoriasis and Hivmentioning

confidence: 99%

Psoriasis: epidemiology, natural history, and differential diagnosis

Basko-Plluska¹,

Petronic‐Rosic²

2012

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated, inflammatory disease which affects primarily the skin and joints. It occurs worldwide, but its prevalence varies considerably between different regions of the world. Genetic susceptibility as well as environmental factors play an important role in determining the development and prognosis of psoriasis. Genomewide association studies have identified many genetic loci as potential psoriasis susceptibility regions, including PSORS1 through PSORS7. Histocompatibility antigen (HLA) studies have also identified several HLA antigens, with HLA-Cw6 being the most frequently associated antigen. Epidemiological studies identified several modifiable risk factors that may predispose individuals to developing psoriasis or exacerbate pre-existing disease. These include smoking, obesity, alcohol consumption, diet, infections, medications and stressful life events. The exact mechanism by which they trigger psoriasis remains to be elucidated; however, existing data suggest that they are linked through Th1-mediated immunological pathways. The natural history of psoriasis varies depending on the clinical subtype as well as special circumstances, including pregnancy and HIV infection. In general, psoriasis is a chronic disease with intermittent remissions and exacerbations. The differential diagnosis is vast and includes many other immunemediated, inflammatory disorders.

show abstract

“…Other topical preparations recorded for use in HIV-infected patients with psoriasis include tar, anthralin, and occlusive therapy. 7 Treatments for localized psoriasis also include salicylic acid and intralesional kenalog. Although these modalities are widely used, there are no published data on their use as treatment of psoriasis in HIV-infected individuals.…”

Section: Results In Hiv Patients Psoriasis That Can Be Treated With Tmentioning

confidence: 99%

Treatment of Psoriasis in HIV-Infected Persons

2011

View full text Add to dashboard Cite

Choosing a treatment modality for psoriasis in HIV-infected patients can be quite a difficult task for dermatologists. These physicians may be reluctant to treat HIV-infected patients with immunosuppressive agents when the host is already immunologically compromised. The available data on safety and efficacy for various psoriasis treatment options in HIV-infected individuals are very limited; yet it is still a physician's duty to provide the best possible treatment for these patients. A revised algorithm is proposed for the treatment of HIV-infected patients with psoriasis based on a previous recommendation from the medical advisory board of the National Psoriasis Foundation. For psoriasis in HIV-infected persons, good HIV control should be the mainstay of treatment. The use of hydroxyurea is reintroduced as an option to consider before the use of systemic immunosuppressant agents. In addition, tumor necrosis factor-α inhibitors may be considered over the oral systemic immunosuppressive agents.

show abstract

HIV and Psoriasis

Cited by 4 publications

References 35 publications

Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity

Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity

Psoriasis: epidemiology, natural history, and differential diagnosis

Treatment of Psoriasis in HIV-Infected Persons

Contact Info

Product

Resources

About